Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
J Periodontal Res ; 49(1): 85-92, 2014 Feb.
Article in English | MEDLINE | ID: mdl-23586845

ABSTRACT

BACKGROUND AND OBJECTIVE: It has been demonstrated that periodontitis induces a systemic inflammation, which may impair endothelial function. Cyclooxygenase-2 (COX-2) is an important enzyme in the inflammatory process and is responsible for prostacyclin production. We hypothesised that in periodontitis, an increase in vascular COX-2 expression may occur, which in turn may have a role in vascular homeostasis. Thus, we evaluated the vascular effects of COX-2 inhibition in an experimental rat model of periodontitis. MATERIAL AND METHODS: Experimental periodontitis was induced in rats by placing a cotton ligature around the cervix of both sides of the mandibular first molars and maxillary second molars. Sham-operated rats had the ligature removed immediately after the procedure. Mesenteric vessels were obtained for the study of COX-2 expression, and blood samples were collected for nitric oxide quantification. In another set of experiments, animals received etoricoxib (10 mg/kg/d, v.o.) or vehicle, and alveolar bone loss and cardiovascular parameters were evaluated. RESULTS: We observed an increase in COX-2 expression in mesenteric vessels harvested from animals with periodontitis, which was accompanied by a reduction in nitric oxide content. Etoricoxib treatment impaired the endothelium-dependent reduction in blood pressure in rats with periodontitis. CONCLUSION: Periodontitis increases vascular COX-2 expression, which is important in the maintenance of vascular homeostasis in this model. Despite the limitations of an animal study, these findings may have important implications regarding the safety of using selective COX-2 inhibitors in patients with periodontitis.


Subject(s)
Arterial Pressure/physiology , Cyclooxygenase 2/physiology , Periodontitis/enzymology , Alveolar Bone Loss/enzymology , Alveolar Bone Loss/prevention & control , Animals , Anti-Inflammatory Agents/pharmacology , Arterial Pressure/drug effects , Cyclooxygenase 2/drug effects , Cyclooxygenase 2 Inhibitors/pharmacology , Disease Models, Animal , Endothelium, Vascular/drug effects , Endothelium, Vascular/enzymology , Etoricoxib , Heart Rate/drug effects , Male , Mesenteric Arteries/enzymology , Nitric Oxide/blood , Periodontitis/prevention & control , Pyridines/pharmacology , Random Allocation , Rats, Wistar , Sulfones/pharmacology , Vasoconstrictor Agents/pharmacology , Vasodilator Agents/pharmacology
2.
J Periodontal Res ; 49(5): 634-41, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24251721

ABSTRACT

BACKGROUND AND OBJECTIVE: It has been demonstrated that periodontitis induces systemic inflammation, which may impair endothelial function leading to increased cardiovascular risk. The aim of this study was to evaluate the effect of simvastatin on systemic inflammatory markers and endothelial dysfunction induced by periodontitis. MATERIAL AND METHODS: Wistar rats were subjected to ligature-induced experimental periodontitis. Eight days after the procedure, the ligature and sham groups were randomly assigned to receive simvastatin or vehicle once a day until the 14th day, when the effects of acetylcholine and sodium nitroprusside on blood pressure were evaluated. Blood samples were collected and evaluated for plasma interleukin-6C, -reactive protein and lipids. The maxilla and mandible were removed for bone loss analysis. RESULTS: Simvastatin treatment reduced systemic inflammation and endothelial dysfunction induced by periodontitis. Furthermore, simvastatin improved the blood lipid profile and reduced alveolar bone loss. CONCLUSION: Simvastatin treatment, in addition to the improvement on serum lipid profile, may reduce other predictors of cardiovascular events associated with periodontitis.


Subject(s)
Endothelium, Vascular/drug effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Inflammation Mediators/immunology , Periodontitis/immunology , Simvastatin/therapeutic use , Acetylcholine/therapeutic use , Alveolar Bone Loss/immunology , Alveolar Bone Loss/prevention & control , Animals , Arterial Pressure/drug effects , C-Reactive Protein/analysis , C-Reactive Protein/drug effects , Disease Models, Animal , Endothelium, Vascular/immunology , Inflammation , Interleukin-6/blood , Leukocyte Count , Lipids/blood , Male , Nitroprusside/therapeutic use , Periodontitis/prevention & control , Random Allocation , Rats , Rats, Wistar , Vasodilator Agents/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL